Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Conditions
Interventions
Bimekizumab
Secukinumab
+1 more
Locations
77
United States
Ps0015 975
Santa Ana, California, United States
Ps0015 939
Danbury, Connecticut, United States
Ps0015 903
Ocala, Florida, United States
Ps0015 921
Ormond Beach, Florida, United States
Ps0015 977
Pembroke Pines, Florida, United States
Ps0015 936
Tampa, Florida, United States
Start Date
June 13, 2018
Primary Completion Date
September 12, 2019
Completion Date
August 9, 2023
Last Updated
April 15, 2026
NCT07337434
NCT06591273
NCT03410992
NCT03370133
NCT03598790
NCT07362017
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions